✦ LIBER ✦

Risperidone in levodopa-induced psychosis in advanced parkinson's disease: An open-label, long-term study

✍ Scribed by Giuseppe Meco; Andrea Alessandri; Patrizia Giustini; Vincenzo Bonifati

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 361 KB
Volume: 12
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870120423

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term, multicenter, open-label stu

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis

✍ M. Davidson; P. D. Harvey; J. Vervarcke; C. A. Gagiano; J. D. De Hooge; G. Bray; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 2 views

Risperidone in the treatment of dopamine

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

✍ Erich Mohr; Tilak Mendis; Kathleen Hildebrand; Peter Paul De Deyn 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 2 views

## Purpose: To evaluate the safety and efficacy of risperidone in patients with parkinson's disease (pd) who are experiencing significant dopamine-induced psychosis. ## Patients and methods: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3

Symptomatic relief from treatment-induce

Symptomatic relief from treatment-induced psychosis in Parkinson's disease: An open-label pilot study with remoxipride

✍ Dr. Tilak Mendis; Erich Mohr; Amanda George; Ilene N. Rusk; Peggy Gray; J. David 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 1 views

## Abstract Current treatment strategies for levodopa‐induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D~2~ receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients exhibiting thought disorder. Symptoms improved sig

Open-label pilot study of levetiracetam

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer

CQP 201-403 in Parkinson's disease: An o

CQP 201-403 in Parkinson's disease: An open-label pilot study

✍ Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in suffici

Long-term effects of tacrine in alzheime

Long-term effects of tacrine in alzheimer's disease: An open study

✍ Sarah A. Eagger; Marcus Richards; Professor Raymond Levy 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 407 KB 👁 2 views

## Abstract To study the efficacy and safety of prolonged tacrine administration, we monitored 41 patients meeting NINCDS–ADRDA criteria for probable Alzheimer's disease while taking tacrine on an open basis for a period of up to 192 weeks. Dependent variables were the Abbreviated Mental Test Score